MedOncMD

To provide the information your oncologist is not telling you or doesn't have the time to!

  • Home
  • Magazine
  • Blog
    • The essentials
    • Art of Oncology
    • Prevention and Healthy Lifestyle
    • Research Advances
    • Navigation Corner
    • Video Library
  • Navigation Corner
  • Meet and Greet
    • About Dr Thomas
    • About Dr Landau
  • Ask MedOncMD?
  • Keep in Touch!

Varied Cancer Perspectives

Explore a comprehensive range of insights and information within our ‘Varied Cancer Perspectives’ category. From melanoma to breast cancer, colorectal cancer to sarcoma, and beyond, this diverse collection delves into the multifaceted world of oncology. Gain a nuanced understanding of different cancer types, treatments, and the latest advancements in research. Whether you’re seeking knowledge on pediatric oncology, uveal melanoma, or desmoid tumors, our curated content provides a holistic view, offering valuable perspectives to empower and inform those navigating the complexities of cancer care. Join us on a journey through varied perspectives, ensuring a well-rounded understanding of the ever-evolving landscape of cancer.

A New Era in Multiple Myeloma Treatment: Isatuximab with VRd Improves Outcomes in Newly Diagnosed Patients

Multiple myeloma (MM) is a type of blood cancer originating in the plasma cells of the bone marrow, leading to an overproduction of abnormal plasma cells. This accumulation disrupts normal blood cell production and results in a range of complications, such as bone pain, anemia, kidney issues, and increased infection risk. Historically, treatment options for …

Read On »

James Van Der Beek’s Colorectal Cancer Diagnosis: A Call to Action for Awareness and Early Detection

In a recent and courageous announcement, actor James Van Der Beek, known for roles in Dawson’s Creek and Varsity Blues, revealed his diagnosis of colorectal cancer. At age 47, Van Der Beek shared that he has been managing this diagnosis privately, taking steps towards treatment with the support of his family. While the specifics indicate …

Read On »

SBRT vs. Conventional Radiotherapy in Prostate Cancer: A New Approach to Treatment

Prostate cancer continues to pose a significant challenge for both patients and healthcare providers. In the realm of radiation therapy, the development of advanced techniques has transformed the landscape of treatment. A recent phase 3 trial comparing Stereotactic Body Radiotherapy (SBRT) to conventional radiotherapy for intermediate-risk prostate cancer provides new insights into how we can deliver effective …

Read On »

A New Frontier in Hodgkin’s Lymphoma Treatment: Nivolumab Plus Chemotherapy

The treatment landscape for advanced-stage classic Hodgkin’s lymphoma (cHL) is rapidly evolving. Traditionally, chemotherapy regimens such as AVD (doxorubicin, vinblastine, dacarbazine) or combinations including brentuximab vedotin have been used to manage this challenging disease. However, a groundbreaking phase 3 clinical trial (S1826) has introduced a promising new regimen—nivolumab (N+AVD)—that is proving to be superior in …

Read On »

FDA Approves Zolbetuximab-Clzb for Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: A New Hope for Patients

On October 18, 2024, the U.S. Food and Drug Administration (FDA) approved zolbetuximab-clzb (Vyloy, Astellas Pharma), a novel treatment for adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. This approval brings a much-needed new option for patients whose tumors express the CLDN18.2 protein, as identified through an FDA-approved test. …

Read On »

A New Standard of Care for EGFR-Mutated NSCLC: The Promise of Amivantamab and Lazertinib

A new article published in the NEJM showing impressive efficacy in NSCLC, here’s the summary below. The landscape of non-small cell lung cancer (NSCLC) treatment continues to evolve, particularly for patients with EGFR mutations. Historically, EGFR tyrosine kinase inhibitors (TKIs) like osimertinib have been the first line of defense, providing improved progression-free survival for patients. …

Read On »

Hope for Advanced Bladder Cancer: Effective New Combination Treatment

Hope for Advanced Bladder Cancer Bladder cancer is often like an unwelcome party crasher, popping up when least expected and causing considerable distress. Yet, in the realm of oncology, we are constantly seeking new ways to send such unwelcome guests packing. Today, I am thrilled to share some exciting news about a promising new approach …

Read On »

GRANITE Immunotherapy Offers Hope for MSS Metastatic Colorectal Cancer: Improving Progression-Free Survival with Neoantigen-Directed Therapy

Immunotherapy has made significant strides in cancer treatment, but microsatellite stable (MSS) metastatic colorectal cancer (mCRC) has long posed a challenge due to its resistance to immune-based therapies. However, promising results from a recent phase 2/3 trial have shown that the individualized neoantigen-directed immunotherapy, GRANITE, may change the outlook for patients with MSS mCRC. This innovative therapy, combined …

Read On »

Brain Tumors: A Closer Look at CNS Malignancies Through the Lives of Dikembe Mutombo and Jimmy Carter

The world recently lost NBA legend Dikembe Mutombo to brain cancer, while former President Jimmy Carter continues to defy expectations. Despite being diagnosed with metastatic melanoma, including brain and liver metastasis he has just celebrated his 100th birthday. These two public figures have brought significant attention to CNS (Central Nervous System) malignancies, sparking curiosity about the different types of brain tumors, how …

Read On »

FDA Approves Inavolisib for Endocrine-Resistant Advanced Breast Cancer: A New Option for PIK3CA-Mutated Patients

On October 10, 2024, the FDA approved a new and promising treatment for patients with advanced breast cancer: inavolisib (Itovebi), in combination with palbociclib and fulvestrant. This new approval offers fresh hope for patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, and HER2-negative breast cancer, especially those whose disease has progressed after endocrine therapy. The approval also includes the FoundationOne Liquid CDx assay, a diagnostic test used to …

Read On »

  • Previous
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • …
  • Page 12
  • Next

Recent Posts

  • The Story Behind the Logo: Building the Bridge, Stone by Stone
  • Remembering Dr. Craig Kitchens: The Legacy of a Great Physician
  • Six Months Later: Rediscovering Balance Through Locum Life and New Ventures
  • When Delay Becomes Harm: A Clinician’s Reflection on Timely Cancer Care
  • Understanding Disability in Oncology: A Clinician’s Perspective

Categories

  • Art of Oncology (78)
  • Current News (12)
  • Immunotherapy News (9)
  • Navigation Corner (6)
  • Prevention and Healthy Lifestyle (18)
  • Research Advances (108)
    • Clinical Trials (43)
    • Immunotherapy (29)
    • New Treatments and Therapies (42)
  • The essentials (41)
    • Radiology (4)
  • Travel Health (1)
  • Uncategorized (10)
  • Varied Cancer Perspectives (114)
    • Biliary tract cancer (3)
    • Bladder Cancer (3)
    • Breast Cancer (10)
    • Cervical Cancer (2)
    • CNS Cancers (1)
    • Colorectal cancer (13)
    • Esophageal Cancer (2)
    • Gastric cancer (6)
    • Hepatic Tumors (1)
    • Leiomyosarcoma (2)
    • Leukemia (2)
    • Lung Cancer (10)
    • Lymphoma (3)
    • Melanoma (28)
    • Multiple Myeloma (3)
    • Neuroendocrine cancer (2)
    • Ovarian Cancer (3)
    • Pancreatic Cancer (5)
    • Prostate Cancer (4)
    • Sarcoma (2)
    • Sickle Cell Disease (4)
    • Skin Cancer (7)
    • Thyroid cancer (1)
    • Urothelial Cancer (1)
  • Video (2)
  • Weekly Newsletter (6)

Get in touch!

  • Facebook
  • Instagram
  • TikTok
  • LinkedIn


Meet the authors

Dr. Sajeve Thomas
Dr Daniel Landau


Subscribe


  • Home
  • Magazine
  • Blog
    • The essentials
    • Art of Oncology
    • Prevention and Healthy Lifestyle
    • Research Advances
    • Navigation Corner
    • Video Library
  • Navigation Corner
  • Meet and Greet
    • About Dr Thomas
    • About Dr Landau
  • Ask MedOncMD?
  • Keep in Touch!
© 2025 MedOncMD. Minimal Theme by SPYR
✕
  • Home
  • Magazine
  • Blog
    • The essentials
    • Art of Oncology
    • Prevention and Healthy Lifestyle
    • Research Advances
    • Navigation Corner
    • Video Library
  • Navigation Corner
  • Meet and Greet
    • About Dr Thomas
    • About Dr Landau
  • Ask MedOncMD?
  • Keep in Touch!